Robin Norris, MD, MS, MPH
- Director, Clinical Research for Oncology, Division of Oncology
- Co-Director, Young Adult Oncology Program, Division of Oncology
- Professor, UC Department of Pediatrics
- robin.norris@cchmc.org
- Board Certified
About
BA: Human Biology, Stanford University, Stanford, CA, 1997.
MD: University of Pennsylvania School of Medicine, Philadelphia, PA, 2001.
MPH: Epidemiology, University of California, Berkeley, CA, 2005.
MS: Translational Research, University of Pennsylvania School of Medicine, Institute for Translational Medicine and Therapeutics, Philadelphia, PA, 2010.
Intern: Pediatrics, University of California, San Francisco, CA, 2001-2002.
Resident: Pediatrics, University of California, San Francisco, CA, 2002-2004.
Fellow: Pediatric Hematology/Oncology, The Children’s Hospital of Philadelphia, Philadelphia, CA, 2005-2008.
Services and Specialties
Research Areas
Locations (2)
Insurance Information
Cincinnati Children's strives to accept a wide variety of health plans. Please contact your health insurance carrier to verify coverage for your specific benefit plan.
Publications
Developing Behavior Change Model-Informed and Participant-Engaged Retention Strategies for Adolescents and Young Adults With Cancer Enrolled on Behavioral and/or Psychosocial Trials. Pediatric Blood and Cancer. 2025; 72:e31583.
Systematic Review of Pain Assessment Measures Used in Pediatric Acute Lymphoblastic Leukemia. Psycho-Oncology: journal of the psychological, social and behavioral dimensions of cancer. 2025; 34:e70063.
Body Image Concerns in Adolescent and Young Adult Oncology Patients within Six Months of Upfront Diagnosis. Journal of Adolescent and Young Adult Oncology. 2024; 13:792-798.
Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients. British Journal of Haematology. 2024; 205:1055-1066.
Feasibility pilot trial of a tailored medication adherence-promotion intervention for adolescents and young adults with cancer: Study design and protocol. Contemporary Clinical Trials. 2024; 139:107483.
Palbociclib in combination with chemotherapy in pediatric and young adult patients with relapsed/refractory acute lymphoblastic leukemia and lymphoma: A Children's Oncology Group study (AINV18P1). Pediatric Blood and Cancer. 2023; 70:e30609.
Clinical trials: A plea to cooperative groups, consortia, pharmaceutical companies, and lead investigators for reasonable imaging protocols. Pediatric Blood and Cancer. 2023; 70:e30362.
Brentuximab vedotin after autologous transplantation in pediatric patients with relapsed/refractory Hodgkin lymphoma. Blood Advances. 2023; 7:3225-3231.
The Choice of Either Conventional Chemotherapy or Inotuzumab Ozogamicin as Bridging Regimen Does Not Appear To Impact Clinical Response to CD19-Directed CAR-T Therapy in Pediatric B-ALL. Transplantation and Cellular Therapy. 2023; 29:311.e1-311.e7.
Barriers to medication adherence among adolescents and young adults with cancer. Pediatric Blood and Cancer. 2023; 70:e30186.
3333 Burnet Avenue, Cincinnati, Ohio 45229-3026
© 1999-2025 Cincinnati Children's Hospital Medical Center. All rights reserved.
Patient Ratings and Comments
All patient satisfaction ratings and comments are submitted by actual patients and verified by a leading independent experience management company, Qualtrics. Patient identities are withheld to ensure confidentiality and privacy. Only those providers whose satisfaction surveys are administered through Cincinnati Children’s Hospital Medical Center are displayed. Click here to learn more about our survey